Literature DB >> 8702845

The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain.

F J Lee1, Z B Pristupa, B J Ciliax, A I Levey, H B Niznik.   

Abstract

In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [3H]dopamine uptake kinetics and [3H]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted. Complete truncation of the carboxyl tail from Ser582 allowed for the expression of biphasic [3H]dopamine uptake kinetics displaying both a low capacity (Vmax approximately 0.4 pmol/10(5) cells/min) high affinity (Km approximately 300 nM) component and one exhibiting low affinity (Km approximately 15 microM] and high capacity (Vmax approximately 5 pmol/10(5)cells/min) with a concomitant 40% decrease in overall apparent Vmax relative to wild type (WT) DAT. Truncation of the last 22 amino acids or substitution of the DAT-COOH tail with sequences encoding the intracellular carboxyl-terminal of either dopamine D1 or D5 receptors produced results that were identical to those with the fully truncated DAT, suggesting that the induction of biphasic dopamine uptake kinetics is likely conferred by removal of DAT-specific sequence motifs distal to Pro597. The attenuation of WT transport activity, either by lowering levels of DAT expression or by pretreatment of cells with phorbol 12-myristate 13-acetate (1 microM), did not affect the kinetics of [3H]dopamine transport. The estimated affinity of dopamine (Ki approximately 180 nM) for all truncated/substituted DAT mutants was 10-fold lower than that of WT DAT (approximately 2000 nM) and appears selective for the endogenous substrate, since the estimated inhibitory constants for numerous putative substrates or uptake inhibitors were virtually identical to those obtained for WT DATs. In marked contrast, DAT truncation/substitution mutants displayed significantly reduced high affinity [3H]CFT binding interactions with estimated Ki values for dopamine and numerous other substrates and inhibitors tested from 10-100-fold lower than that observed for WT DAT. Moreover, co-expression of truncated and/or substituted DATs with WT transporter failed to reconstitute functional or pharmacological activities associated with both transporters. Instead, complete restoration of uniphasic low affinity [3H]dopamine uptake kinetics (Km approximately 2000 nM) and high affinity substrate and inhibitor [3H]CFT binding interactions attributable to WT DATs were evident. These data clearly suggest the functional independence and differential regulation of the dopamine translocation process from the characteristics exhibited by its ligand binding domain. The lack of functional phenotypic expression of mutant DAT activities in cells co-expressing WT transporter is consistent with the contention that native DATs may exist as multisubunit complexes, the formation and maintenance of which is dependent upon sequences encoded within the carboxyl tail.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702845     DOI: 10.1074/jbc.271.34.20885

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.

Authors:  Mitchell Ho; Mariangela Segre
Journal:  Biochim Biophys Acta       Date:  2003-07-30

Review 2.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.

Authors:  Houbo Jiang; Yong Ren; Eunice Y Yuen; Ping Zhong; Mahboobe Ghaedi; Zhixing Hu; Gissou Azabdaftari; Kazuhiro Nakaso; Zhen Yan; Jian Feng
Journal:  Nat Commun       Date:  2012-02-07       Impact factor: 14.919

Review 4.  Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders.

Authors:  Amy F T Arnsten; Min Wang; Constantinos D Paspalas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 5.  Model systems for analysis of dopamine transporter function and regulation.

Authors:  Moriah J Hovde; Garret H Larson; Roxanne A Vaughan; James D Foster
Journal:  Neurochem Int       Date:  2018-09-01       Impact factor: 3.921

6.  Molecular cloning and characterization of an L-epinephrine transporter from sympathetic ganglia of the bullfrog, Rana catesbiana.

Authors:  S Apparsundaram; K R Moore; M D Malone; H C Hartzell; R D Blakely
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

7.  Membrane trafficking regulates the activity of the human dopamine transporter.

Authors:  H E Melikian; K M Buckley
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

8.  Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.

Authors:  A C Thompson; A Zapata; J B Justice; R A Vaughan; L G Sharpe; T S Shippenberg
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

9.  A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation.

Authors:  Bipasha Guptaroy; Minjia Zhang; Erica Bowton; Francesca Binda; Lei Shi; Harel Weinstein; Aurelio Galli; Jonathan A Javitch; Richard R Neubig; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2008-12-19       Impact factor: 4.436

10.  Restoration of cocaine stimulation and reward by reintroducing wild type dopamine transporter in adult knock-in mice with a cocaine-insensitive dopamine transporter.

Authors:  Haiyin Wu; Brian O'Neill; Dawn D Han; Keerthi Thirtamara-Rajamani; Yanlin Wang; Howard H Gu
Journal:  Neuropharmacology       Date:  2014-05-13       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.